Niurka Meneses
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Niurka Meneses has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- A. Türler
Department of Chemistry, Biochemistry and Pharmaceutical Sciences, Faculty of Science, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland
1 shared publication - Josue M. Bermudez
Department of Chemistry and Biochemistry, University of Bern, 3012 Bern, Switzerland
1 shared publication - José A. Galván
Institute of Pathology, University of Bern, Bern, Switzerland
1 shared publication - Kayluz Frias Boligan
Institute of Pharmacology (PKI), University of Bern, 3010 Bern, Switzerland
1 shared publication - Manfred Heller
Proteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, 3012 Bern, Switzerland
1 shared publication - Matthias Miederer
Department of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany
1 shared publication
Latest Publications
- Open Access
- 28 November 2018
- Published by MDPI AG in Pharmaceuticals
- Vol. 11 (4) , 132
Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo
Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with 177Lu has been used in clinical trials for radioimmunotherapy (RIT) of RCCs. In this work, an extensive characterization of the immunoconjugates allowed optimization of the labeling conditions with 177Lu while maintaining immunoreactivity of cG250, which was then investigated in in vitro and in vivo experiments. cG250 was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (DOTA(SCN)) by using incubation times between 30 and 90 min and characterized by mass spectrometry. Immunoconjugates with five to ten DOTA(SCN) molecules per cG250 molecule were obtained. Conjugates with ratios less than six DOTA(SCN)/cG250 had higher in vitro antigen affinity, both pre- and postlabeling with 177Lu. Radiochemical stability increased, in the presence of sodium ascorbate, which prevents radiolysis. The immunoreactivity of the radiolabeled cG250 tested by specific binding to SK-RC-52 cells decreased when the DOTA content per conjugate increased. The in vivo tumor uptake was < 10% ID/g and independent of the total amount of protein in the range between 5 and 100 µg cG250 per animal. Low tumor uptake was found to be due to significant necrotic areas and heterogeneous CAIX expression. In addition, low vascularity indicated relatively poor accessibility of the CAIX target.
- 28 November 2018
- Published by MDPI AG in Pharmaceuticals
- Vol. 11 (4) , 132
Open AccessEvaluation of Radiolabeled Girentuximab In Vitro and In Vivo
Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with 177Lu has been used in clinical trials for radioimmunotherapy (RIT) of RCCs. In this work, an extensive characterization of the immunoconjugates allowed optimization of the labeling conditions with 177Lu while maintaining immunoreactivity of cG250, which was then investigated in in vitro and in vivo experiments. cG250 was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (DOTA(SCN)) by using incubation times between 30 and 90 min and characterized by mass spectrometry. Immunoconjugates with five to ten DOTA(SCN) molecules per cG250 molecule were obtained. Conjugates with ratios less than six DOTA(SCN)/cG250 had higher in vitro antigen affinity, both pre- and postlabeling with 177Lu. Radiochemical stability increased, in the presence of sodium ascorbate, which prevents radiolysis. The immunoreactivity of the radiolabeled cG250 tested by specific binding to SK-RC-52 cells decreased when the DOTA content per conjugate increased. The in vivo tumor uptake was < 10% ID/g and independent of the total amount of protein in the range between 5 and 100 µg cG250 per animal. Low tumor uptake was found to be due to significant necrotic areas and heterogeneous CAIX expression. In addition, low vascularity indicated relatively poor accessibility of the CAIX target.